| Abstrakt: |
A study conducted by researchers at the Harbin Institute of Technology in China has found that neoadjuvant immunochemotherapy (NICT) can improve the clinical outcomes of patients with esophageal cancer. The study compared the therapeutic effects and survival periods of patients who underwent surgery alone, neoadjuvant chemotherapy (NCT), and NICT. The results showed that patients in the NICT group had better clinical responses and survival rates compared to the NCT group. NICT was found to promote the expression of immune-related genes and activate CD8+ T and CD16+ NK cells, leading to the killing of esophageal cancer cells. This study provides evidence for the potential of NICT as a treatment strategy for esophageal cancer. [Extracted from the article] |
